Sanders goes af­ter NIH for grant­i­ng ex­clu­sive patent for po­ten­tial can­cer ther­a­py

Sen­ate Health Com­mit­tee Chair Bernie Sanders (I-VT) is call­ing on the HHS in­spec­tor gen­er­al to in­ves­ti­gate an NIH pro­pos­al to grant an ex­clu­sive patent li­cense to a small and “ob­scure” phar­ma com­pa­ny for a po­ten­tial CAR-T treat­ment for cer­vi­cal can­cer, de­vel­oped so far with NIH funds.

In a let­ter penned to HHS In­spec­tor Gen­er­al Christi Grimm Mon­day af­ter­noon, Sanders takes is­sue with an NIH pro­pos­al pub­lished last month to grant an ex­clu­sive patent li­cense to the com­pa­ny Scar­let TCR for a gene ther­a­py to treat cer­vi­cal can­cer. He said the ther­a­py, which could po­ten­tial­ly be worth bil­lions, was de­vel­oped by the NIH, al­though it re­mains un­clear how the CAR-T’s po­ten­tial worth was de­ter­mined.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER